Bortezomib-based regimen for the treatment of 110 multiple myeloma patients

National Medical Journal of China

Volumn 90, Issue 38, 2010, Pages 2671-2674

  Yang, Guang Zhong ^a   Chen, Wen Ming ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Multiple myeloma; Therapy

Indexed keywords

BORTEZOMIB; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG DOSE REGIMEN; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PLASMACYTOMA; REMISSION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84871413308     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.38.003     Document Type: Article

References (18)

1. 2008, 17: 325-327.
2. Kyle R A, Rajkumar S V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia, 2009, 23: 3-9.
3. Durie B G, Harousseau J L, Miguel J S, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006, 20: 1467-1473.
4. Trotti A, Colevas A D, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 2003, 13: 176-181.
5. Greipp P R, Miguel J S, Durie B, et al. International staging system for multiple myeloma. J Clin Oncol, 2005, 23: 3412-3420.
6. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood, 2009, 114: 1046-1052.
7. Richardson P G, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol, 2009, 27: 3518-3525.
8. Popat R, Oakervee H, Williams C, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol, 2009, 144: 887-894.
9. Reeder C B, Reece D E, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia, 2009, 23: 1337-1341.
10. Shaughnessy J D, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol, 2009, 147: 347-351.
11. Palumbo A, Rajkumar S V. Treatment of newly diagnosed myeloma. Leukemia, 2009, 23: 449-456.
12. Jagannath S, Barlogie B, Berenson J R, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol, 2008, 143: 537-540.
13. Roussel M, Moreau P, Huynh A, et al. Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase II study of the Intergroupe Francophone du Myelome (IFM). Blood, 2010, 115: 32-37.
14. Kasahara I, Nishio M, Yamamoto S, et al. Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib. Int J Hematol, 2009, 90: 413-415.
15. Sood R, Carloss H, Kerr R, et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol, 2009, 84: 657-660.
16. Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol, 2010, 21: 325-330.
17. Badros A, Goloubeva O, Dalai J S, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer, 2007, 110: 1042-1049.
18. Basler M, Lauer C, Beck U, et al. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol, 2009, 183: 6145-6150.